Arovella Therapeutics Ltd. announced that David Simmonds, non-executive director, will retire from the board of directors at the 2023 Annual General Meeting, expected to be held on 10 November, and will not stand for re-election. Mr. Simmonds was appointed to the Board of Directors in March 2019. Since that time, he has served the company admirably and played an important role in the company's transition to focus on its iNKT cell therapy platform for cancer treatment.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.12 AUD | +4.35% | +14.29% | +4.35% |
Mar. 26 | Arovella Therapeutics Receives Firm Commitments for About AU$12.5 Million Raise | MT |
Mar. 20 | Arovella Therapeutics' ALA-101-onCARlytics Collaboration with Imugene Ends; Shares Down 12% | MT |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+4.35% | 82.18M | |
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- ALA Stock
- News Arovella Therapeutics Limited
- Arovella Therapeutics Limited Announces Retirement of David Simmonds as Non-Executive Director